Observational studyBMC cancer2026
Aumolertinib in non-small cell lung cancer with uncommon EGFR exon 19 deletions: a real-world dual-center study.
Observational study in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEpidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) (EGFR-TKIs) show heterogeneous responses in patients with non-small cell lung cancer (NSCLC) harboring uncommon EGFR exon 19 deletion (E19del) mutations. This study evaluated the efficacy of second- and third-generation (2G/3G) EGFR-TKIs as first-line therapy in NSCLC patients with uncommon E19del variants.
methodsThis dual-center retrospective study included 118 patients with advanced or recurrent NSCLC harboring uncommon EGFR E19del mutations (excluding E746_A750del). All patients received first-line treatment with 2G/3G EGFR-TKIs. Molecular profiling was performed using next-generation sequencing. Progression-free survival (PFS) was analyzed across TKI subtypes and deletion categories. Molecular modeling was performed to evaluate the drug-binding affinities.
resultsAmong the 12 identified E19del subtypes, L747_P753delinsS (21.2%) and L747_T751del (20.3%) were predominant, with an overall median PFS (mPFS) of 15.5 months. The differences in mPFS were observed across specific TKIs: aumolertinib (15.9 months), osimertinib (15.5 months), furmonertinib (15.0 months) and afatinib (12.2 months). No difference in PFS was observed between 2G (12.2 months) and 3G TKIs (15.5 months; P = 0.19). The subgroup analysis revealed numerically shorter mPFS for T751-deletions (9.4 months) compared to E746-deletions (15.7 months) or L747-deletions (14.8 months). Aumolertinib demonstrated consistent PFS regardless of deletion subtypes, whereas osimertinib-treated group exhibited subtype-dependent efficacy. Molecular modeling confirmed a stronger binding affinity of aumolertinib than osimertinib across prevalent L747-deletion variants.
conclusionsThis comparative study demonstrated the improved and consistent activity of aumolertinib across diverse uncommon EGFR E19del subtypes compared to osimertinib, due to its enhanced binding affinity and structural adaptability. These findings support molecular subtype-guided TKI selection, aumolertinib as a first-line option for patients harboring uncommon EGFR E19del variants, particularly in settings lacking comprehensive molecular stratification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.